Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
D1.19 - Etoricoxib-Induced Fixed Drug Eruption: A Case Series and Assessment of Tolerance to Alternative NSAIDs
D1.27 - Delayed Hypersensitivity Reactions to Iodinated Contrast Media: Diagnostic Outcomes and Alternative Selection
D1.17 - Service Evaluation of patients with Suspected Allergic Reactions presenting to the Emergency Department of a tertiary Irish teaching hospital
D1.18 - Not Just for Kids: A Rare Case of Adult-Onset IgE-Mediated Cow’s Milk Allergy Masquerading as Drug Hypersensitivity
D1.20 - Challenges in Safe Alternative Selection in a Case of Amoxicillin-Induced Anaphylaxis
D1.21 - Three cases of Food induced Anaphylaxis - Role of Cofactors
D1.25 - Cannabis-Fruit-Veggie Syndrome: From Respiratory Symptoms to Life-Threatening Anaphylaxis
D1.26 - Egg Allergy Persistence Beyond 8 Years of Age
D1.28 - Clinical Follow-up in Radiocontrast Media–Induced Hypersensitivity Reactions: Beyond the Reaction
D1.29 - When Anaphylaxis Is Not Anaphylaxis: A Rare Differential Diagnosis in Perioperative Shock
D1.30 - Allergy Care in Adult Cystic Fibrosis Patients with Drug Hypersensitivity: A Service Evaluation at St Bartholomew’s Hospital
D1.31 - Identification of Process-Modified Allergens in Tiger Nut Milk (Horchata) as the Cause of IgE-Mediated Anaphylaxis: Molecular Evidence of Aldolase and α/β-Hydrolase Proteins
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download